Eli Lilly and Company (NYSE:LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on December ...

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly and Company (NYSE:LLY)’s popular drug Mounjaro will be added to China’s state-run health insurance program starting ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly ( LLY) snapped nine straight sessions of losses on Wednesday after its shares settled 1.16% higher at $993.64. The ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

On Friday, an EMA committee recommended extending the use of Eli Lilly's type 2 diabetes drug, Mounjaro, to children as young ...

The European Medicines Agency’s, EMA, committee recommended a change to extend the use of Eli Lilly’s (LLY) Mounjaro for the treatment of type 2 ...